Buying speculative healthcare stocks during an almost decade-long bull market might sound like a shaky proposition. But this is no ordinary bull market. The global push to legalize marijuana, combined with the advent of game-changing new medical treatments, has provided a sound basis for the sector’s steady rise northward. Even so, the best may be yet to come.
The biotech CRISPR Therapeutics (NASDAQ:CRSP) and cannabis giant Curaleaf Holdings (NASDAQOTH:CURLF) are two names experiencing a rapid upward trajectory in 2019. Despite their enormous gains so far this year, these two red-hot growth stocks appear to have a lot more room to run based on their long-term prospects. In fact, I’m considering adding… Continue reading at Fool.com